New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
08:18 EDTAPRIApricus Biosciences announces launch of topical
Apricus Biosciences announced the launch of Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction, or ED, by the Sandoz Division of the Novartis Group of Companies, in Sweden. According to the most recent estimates, the European Erectile Dysfunction Market in 2013 was above $1.3B, and analyst estimates for ex-US Vitaros sale are approximately $300M at peak. Apricus continues to receive multiple commercial product orders of Vitaros from its partners, and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The commercialization of Vitaros has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200M in potential milestone payments.
News For APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:35 EDTAPRIApricus Biosciences appoints Barbara Troupin, M.D. as Chief Medical Officer
Subscribe for More Information
December 8, 2014
16:03 EDTAPRIApricus Biosciences files to sell 3.42M share for selling stock holder
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use